HOOKIPA Pharma Inc.
HOOK · OTC
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.00 | 0.04 | 0.00 |
| FCF Yield | 0.24% | -83.09% | -32.53% | -18.31% |
| EV / EBITDA | 1.74 | 0.56 | 0.23 | -0.35 |
| Quality | ||||
| ROIC | -39.51% | -36.22% | -22.31% | -22.41% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | -0.00 | 0.84 | 1.26 | 0.75 |
| Growth | ||||
| Revenue 3-Year CAGR | -16.36% | 45.56% | 69.23% | 63.38% |
| Free Cash Flow Growth | 100.15% | -19.39% | -21.62% | 40.59% |
| Safety | ||||
| Net Debt / EBITDA | 2.64 | 1.59 | 4.33 | 3.93 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 373.07 | 1,573.34 | 478.23 | -4,953.28 |